Interestingly, Urszula M Domanska et al. [21] and Arun Bhardwaj et al. [22] coincidentally reported the counteracting effect between CXCL12/CXCR4 signaling and docetaxel treatment, and inhibition of this axis can significantly sensitize prostate cancer to docetaxel treatment. This evidence concerns the gene CXCL12 and prostate carcinoma.